Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Purplepayday Jul. 3 at 12:22 PM

$PPBT .. explanation for the huge dilution 👍

4 · Reply

crs1 Jul. 2 at 7:34 PM

$PPBT Our management has no value.

1 · Reply

Purplepayday Jul. 2 at 6:18 PM

$PPBT Fails to deliver (FTD) on the 11th June was 626K 👀

1 · Reply

Purplepayday Jul. 2 at 2:19 PM

$PPBT $0.69

0 · Reply

Winorbust Jul. 2 at 2:18 PM

$PPBT unfortunately shareholders were scammed here. Drops are normal because the company is essentially broke without dilution

0 · Reply

Stocktelligence Jul. 2 at 1:57 PM

$PPBT

1 · Reply

Mantraset3 Jul. 2 at 5:33 AM

$PPBT $69

0 · Reply

65creedmore Jul. 2 at 2:14 AM

$PPBT what’s with the after hours drop?

0 · Reply

BitterTwit2 Jul. 2 at 12:41 AM

$PPBT I was confused by the 80% drop in message volume on this board, until I realized Smitty blocked me... 😆

1 · Reply

LetItRip675 Jul. 1 at 4:30 PM

$PPBT I need a cigarette

0 · Reply

Purple Biotech presents new IM1240 data at EACR

2026-05-20T21:35:38.000Z - 6 weeks ago

Purple Biotech files $200M mixed securities shelf

2026-04-27T11:44:09.000Z - 2 months ago

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

2026-03-25T12:17:12.000Z - 3 months ago

Purple Biotech announces collaboration with Converge Bio

2026-03-17T11:31:37.000Z - 3 months ago

Purple Biotech regains compliance with Nasdaq

2026-03-13T17:47:18.000Z - 4 months ago

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

2026-03-13T12:13:32.000Z - 4 months ago

Purple Biotech CEO Gil Efron to step down in August

2026-03-13T12:07:41.000Z - 4 months ago

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

Fri, 13 Mar 2026 08:04:00 -0400 - 4 months ago

Purple Biotech Announces CEO Transition

2026-02-28T00:50:34.000Z - 4 months ago

Purple Biotech trading halted, news pending

2026-02-25T22:35:50.000Z - 4 months ago

Purple Biotech to implement ADS ratio change

Wed, 25 Feb 2026 16:20:00 -0500 - 4 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

2026-01-07T13:05:42.000Z - 6 months ago

Purple Biotech completes toxicology study of IM1240

2025-12-11T12:26:28.000Z - 7 months ago

Purple Biotech’s antibody platform shows anti-tumor activity

Dec 4, 2025, 7:00 AM EST - 7 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

2025-11-14T13:11:08.000Z - 8 months ago

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

2025-11-14T13:10:49.000Z - 8 months ago

Purple Biotech sees cash runway into 1H27

Nov 14, 2025, 8:00 AM EST - 8 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-29T13:21:27.000Z - 8 months ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

2025-10-29T11:41:23.000Z - 8 months ago

Purple Biotech achieves manufacturing milestone for IM1240

Oct 29, 2025, 7:33 AM EDT - 8 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

2025-10-20T20:05:22.000Z - 9 months ago

Purple Biotech receives noncompliance notification from Nasdaq

Oct 20, 2025, 4:00 PM EDT - 9 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

2025-09-10T12:10:31.000Z - 10 months ago

Purple Biotech receives intention to grant a European patent covering NT219

Sep 5, 2025, 4:00 PM EDT - 10 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

2025-09-04T13:20:09.000Z - 10 months ago

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

2025-09-04T11:20:09.000Z - 10 months ago

Purple Biotech announces new data on IM1240

PPBT

2025-09-03T11:06:00.000Z - 10 months ago

Purple Biotech expands CAPTN-3 portfolio with IM1305

PPBT

2025-08-29T13:20:14.000Z - 11 months ago

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

PPBT

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-06T11:21:25.000Z - 11 months ago

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

PPBT

Aug 6, 2025, 7:00 AM EDT - 11 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 2 years ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 2 years ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 2 years ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purplepayday Jul. 3 at 12:22 PM

$PPBT .. explanation for the huge dilution 👍

4 · Reply

crs1 Jul. 2 at 7:34 PM

$PPBT Our management has no value.

1 · Reply

Purplepayday Jul. 2 at 6:18 PM

$PPBT Fails to deliver (FTD) on the 11th June was 626K 👀

1 · Reply

Purplepayday Jul. 2 at 2:19 PM

$PPBT $0.69

0 · Reply

Winorbust Jul. 2 at 2:18 PM

$PPBT unfortunately shareholders were scammed here. Drops are normal because the company is essentially broke without dilution

0 · Reply

Stocktelligence Jul. 2 at 1:57 PM

$PPBT

1 · Reply

Mantraset3 Jul. 2 at 5:33 AM

$PPBT $69

0 · Reply

65creedmore Jul. 2 at 2:14 AM

$PPBT what’s with the after hours drop?

0 · Reply

BitterTwit2 Jul. 2 at 12:41 AM

$PPBT I was confused by the 80% drop in message volume on this board, until I realized Smitty blocked me... 😆

1 · Reply

LetItRip675 Jul. 1 at 4:30 PM

$PPBT I need a cigarette

0 · Reply

Winorbust Jul. 1 at 11:47 AM

$PPBT well to your last question, scam companies in the market literally have nothing to do with Trump, nor can he physically do anything about it. It’s capitalism, but it’s up to the SEC to stop scams. But our SEC is bought and paid for and corrupt! As for bleeding us dry in general. He’s tried to level the playing field, bring business back home, and make new trade deals, but the democrats try to stop him at every turn

0 · Reply

coinspitter Jul. 1 at 11:04 AM

$PPBT wen buyout?

0 · Reply

JuggernautRaider Jul. 1 at 9:57 AM

$PPBT yet another Israeli SXAM. CM24 could SAVE PANCREATIC CANCER LIVES. GIL EFRON SHOULD BE IN PRISON JUST LIKE NETANYAHOO 🇺🇸 🇺🇸 🇺🇸 LOCK THEM UP, TRUMP! Where are you on this? EVERY OTHER COUNTRY IS BLEEDING US DRY LIKE THE VAMPIRES THEY ARE 🩸

0 · Reply

Winorbust Jun. 30 at 11:52 PM

$PPBT $SDOT that’s hilarious.. PPBT is basically broke. And the only way they keep the lights on and their insane salaries going is through dilution. 3 reverse splits so far. It’s so bad that -most- long term shareholders need $300-800+ just to break even With some over $1000 lol

1 · Reply

Mantraset3 Jun. 30 at 7:52 PM

$PPBT this will go to $69 like $SDOT

1 · Reply

teeman Jun. 30 at 6:06 PM

$PPBT Does this volume have any significance? I think so.

1 · Reply

demo1one Jun. 30 at 3:45 PM

$PPBT

0 · Reply

demo1one Jun. 30 at 3:44 PM

$PPBT $CCCC

0 · Reply

dumbbuyoops Jun. 30 at 1:20 PM

$PPBT lost 50k here and know of at least 50-75 others that lost their ass on this over the last 3-4 years. Took me almost 2.5 years to get close to green all time. This is where money goes to die

2 · Reply

Mantraset3 Jun. 30 at 11:19 AM

$PPBT to the moon 🌙 today lol

0 · Reply

Wkdwalker Jun. 29 at 3:47 PM

$PPBT wonder what happened to the 5m shares

3 · Reply

Stocktelligence Jun. 29 at 2:24 PM

$PPBT

0 · Reply

Market Cap	1.58M
Revenue (ttm)	0.00
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	47,200
Avg Vol	376,900
Day's Range	N/A - N/A
Shares Out	929,000.00
Stochastic %K	38%
Beta	0.68
Analysts	Sell
Price Target	$30.00